Business
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"\nEB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds\n\n\nEnveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nEnveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the Company is prioritizing the development of EB-003, its first-in-class approach to address difficult-to-treat mental health disorders. EB-003 and other neuroplastogens developed by Enveric are designed to promote neuroplasticity without inducing hallucinations, a hallmark side effect of many psychedelic and psychedelic-inspired compounds. Enveric is currently advancing pre-clinical development activities for EB-003 and targeting a Pre-IND meeting with the U.S. Food and Drug Administration (FDA) for early 2025.\n\n\n“EB-003 has the potential to be a breakthrough neuroplastogen drug candidate that offers the ability to treat resistant mental health disorders without the hallucinogenic effect typically associated with psychedelic-based molecules,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “Minimizing the hallucinatory effect is vital for the clinical development of EB-003 since it will allow for truly blinded placebo-controlled clinical trials and eliminate the need for co-administration of psychotherapy. In addition, minimizing the hallucinatory effect will enable the administration of such therapies in an outpatient setting, and support a more widespread acceptance for psychedelic-inspired drugs.”\n\n\nDr. Tucker continued, “The potential advantages of EB-003 were underscored during the recent U.S. FDA Psychopharmacologic Drugs Advisory Committee for Lykos Therapeutics’ MDMA-assisted therapy (Lykos Adcom). During the Lykos Adcom meeting, the advisory committee raised several issues that likely will need to be overcome by hallucination-inducing psychedelics currently in development. Notably, ‘expectation bias’ and the inability to adequately blind both patients and study monitors due to the psychedelic properties of the Lykos candidate...